Cognitive and Functional Assessment of Psychosis Stratification Study (CoFAPSS)

Prediction of treatment response and illness trajectory in psychotic disorders including schizophrenia, bipolar affective disorder, schizoaffective disorder, and psychotic depression is difficult due to heterogeneity in presentation and outcome. Consequently, patients may receive prolonged ineffective treatments leading to functional decline, illness chronicity, and iatrogenic physical illness. One approach to addressing these problems is to stratify patients based on historical, clinical, and biological signatures. Such an approach has the potential to improve categorization resulting in better understanding of underlying mechanisms and earlier evidence-based treatment with reduced side effect burden. To investigate these multimodal signatures we developed the Cognitive and Functional Assessment of Psychosis Stratification Study (CoFAPSS) employing a prospective study design and a healthy control group comparison. The main aim of this study is to investigate cognitive, and biological "genomics" markers of psychotic illnesses that can be integrated with clinical data to improve prediction of risk and define functional trajectories. We also aim to identify biological "genomic" signatures underpinning variation in treatment response and adverse medical outcomes. The study commenced in June 2016, including patients with primary diagnosis of psychotic disorders including schizophrenia, bipolar affective disorder, schizoaffective disorder, and psychotic depression according to DSM-5 criteria. The assessment covers a wide range of participant history (life stressors, trauma, and family history), cognitive dimensions (social perception, memory and learning, attention, executive function, and general cognition), measures to assess psychosocial function and quality of life, psychotic symptom severity, clinical course of illness, and parameters for adverse medical outcome. Blood is collected for comprehensive genomic discovery analyses of biological (genomic, transcriptomic, proteomic, and cell-biologic) markers. The CoFAPSS is a novel approach that integrates clinical, cognitive and biological "genomic" markers to clarify clinico-pathological basis of risk, functional trajectories, disease stratification, treatment response, and adverse medical outcome. The CoFAPSS team welcomes collaborations with both national and international investigators

Bipolar disorder · Cognition · Psychiatry · Psychosis · Psychosocial · Schizoaffective disorder · Schizophrenia (object-oriented programming · Bipolar Disorder and Treatment · Clinical Psychology · Medicine · Psychology · Schizophrenia research and treatment · Tryptophan and brain disorders

• Working-memory capacity and the control of attention

  Michael J Kane, Randall W Engle•Journal of Experimental…•2003

  Incluir item

• Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016

  Open Access•Theo Vos, Amanuel Alemu Abajobir et al.•The Lancet•2017

  Incluir item

• The Columbia–Suicide Severity Rating Scale

  Kelly Posner, Gregory K Brown et al.•American Journal of Psychiatry•2011

  Incluir item

• Machine Learning Approaches for Clinical Psychology and Psychiatry

  Dominic B Dwyer, Peter Falkai et al.•Annual Review of Clinical…•2018

  Incluir item

• Wgcna

  Open Access•Peter Langfelder, Steve Horvath•BMC Bioinformatics•2008

  Incluir item

• Research Domain Criteria (RDoC)

  Thomas R Insel, Thomas Insel et al.•American Journal of Psychiatry•2010

  Incluir item

• The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)

  Christopher Randolph, Michael C Tierney et al.•Journal of Clinical and…•1998

  Incluir item

• Global, regional, and national disability-adjusted life-years (Dalys) for 359 diseases and injuries and healthy life expectancy (Hale) for 195 countries and territories, 1990–2017

  Open Access•Hmwe Hmwe Kyu, D Abate et al.•The Lancet•2018

  Incluir item

• Specific impairments of planning

  Open Access•Timothy Shallice•Philosophical transactions of the…•1982

  Incluir item

• A Systematic Review of Mortality in Schizophrenia

  Sukanta Saha, David Chant et al.•Archives of General Psychiatry•2007

  Incluir item

• Assessing the Performance of Prediction Models

  Ewout W Steyerberg, Andrew J Vickers et al.•Epidemiology•2010

  Incluir item

• Global, regional, and national disability-adjusted life-years (Dalys) for 333 diseases and injuries and healthy life expectancy (Hale) for 195 countries and territories, 1990–2016

  Open Access•Simon I Hay, Amanuel Alemu Abajobir et al.•The Lancet•2017

  Incluir item

• The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia

  Stanley R Kay, Abraham Fiszbein et al.•Schizophrenia Bulletin•1987

  Incluir item

• Clinical, Functional, and Biological Correlates of Cognitive Dimensions in Major Depressive Disorder – Rationale, Design, and Characteristics of the Cognitive Function and Mood Study (CoFaM-Study)

  Open Access•Bernhard T Baune, Tracy Air•Frontiers in Psychiatry•2016

  Incluir item

• Content validation of two SF-36 subscales for use in type 2 diabetes and non-dialysis chronic kidney disease-related anemia

  Open Access•Mona L Martin, Donald L Patrick et al.•Quality of Life Research•2010

  Incluir item

• Validation and calibration of the SF-36 health transition question against an external criterion of clinical change in health status

  Open Access•Stephanie A Knox, Stephanie Knox et al.•Quality of Life Research•2009

  Incluir item

• Assessment of differential item functioning in the Perceived Stress Scale-10

  Stephen R Cole•Journal of Epidemiology and…•1999

  Incluir item